Skip to main content
Erschienen in: Diabetology & Metabolic Syndrome 1/2017

Open Access 01.12.2017 | Research

Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study

verfasst von: Ramin Heshmat, Motahar Heidari, Hanieh-Sadat Ejtahed, Mohammad Esmaeil Motlagh, Armita Mahdavi-Gorab, Hasan Ziaodini, Majzoubeh Taheri, Gita Shafiee, Shaghayegh Beshtar, Mostafa Qorbani, Roya Kelishadi

Erschienen in: Diabetology & Metabolic Syndrome | Ausgabe 1/2017

Abstract

Background

The purpose of the present study was to assess the validity of continuous metabolic syndrome score (cMetS) for predicting metabolic syndrome (MetS) and to determine the cutoff values in a representative sample of Iranian children and adolescents.

Methods

This national study was conducted among 3843 students, aged 7–18 years country during the fifth survey of a national school-based surveillance program. The cMetS was computed by standardizing the residuals of waist circumference, mean arterial blood pressure, high-density lipoprotein cholesterol, triglycerides, and glucose by regressing them according to age and sex and aggregating them. The optimal cut-off points of cMetS for predicting MetS were determined by the receiver operation characteristic (ROC) curve analysis in different gender and age categories.

Results

Totally, 3843 students (52.3% boys) with average age of 12.45 years were assessed. The mean of cMetS increased according to elevating the number of MetS components. The overall cMetS cut-off point was 1.76 (sensitivity 93% and specificity 82%) in total pediatrics. The area under the ROC curve was 94%. The values for boys and girls were 1.79 and 2.72, respectively.

Conclusions

cMetS performed highly accurate in predicting pediatrics with MetS in all gender and age groups and it appears to be a valid index in children and adolescents.
Hinweise
Roya Kelishadi and Mostafa Qorbani contributed equally to this work
Abkürzungen
cMetS
continuous metabolic syndrome score
MetS
metabolic syndrome
WC
waist circumference
MAP
mean arterial blood pressure
ROC
receiver operation characteristic
AUC
area under the curve
TG
triglycerides
BP
blood pressure
HDL-C
high density lipoprotein-cholesterol
CASPIAN
Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease
BMI
body mass index
FBG
fasting blood glucose
TC
total cholesterol
LDL-C
low density lipoprotein-cholesterol

Background

Metabolic syndrome (MetS) is characterized by co-existence of abdominal adiposity, elevated levels of blood pressure (BP), serum triglycerides (TG) and glucose, as well as low serum high density lipoprotein-cholesterol (HDL-C). MetS increases the morbidity and mortality of most chronic diseases [1, 2].
MetS is well defined in adults, however in the pediatric age group, there is no universal and uniform definition for MetS. Many studies in children and adolescents use the adult definitions with modified cutoff points for each component [3, 4].
The prevalence of MetS in children and adolescents has large variations in different studies. Therefore, modeling the relationship between risk factors and categorical variables of MetS and the use of discriminant function or multiple logistic regression analysis revealed controversial findings. Thus, a continuous value of metabolic risk score (cMetS) has been suggested for overcoming these limitations [5, 6].
Epidemiological studies that investigated cardio-metabolic risk factors among children and adolescents used various scores and statistical approaches to calculate the cMetS. Different variables are used in cMetS as indicators of obesity, lipids, glucose or insulin, BP and other components including smoking or physical activity. Various statistical approaches including principal component analysis, standardized residuals of Z-scores, and centile rankings have been applied because of the differences in variables included in the definition [5, 7, 8].
Utility of the cMetS is increasing in pediatric epidemiological research. The purpose of the present study is to construct cMetS in a large nationally representative sample of Iranian children and adolescents and to evaluate the efficacy and validity of this score in predicting the risk of MetS components. In addition, we determined cutoff points for cMetS score that were stratified by age and gender for identifying MetS in the pediatrics.

Methods

Study design and population

The data of present study were collected as a part of the fifth phase of a national school-based surveillance survey entitled “Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease” (CASPIAN V) in 2015. Totally 14,400 individuals aged 7–18 years participated in the survey. Sampling was conducted by multistage, stratified cluster sampling method from urban and rural areas of 30 provinces in Iran. Students with Iranian nationality, without any history of chronic diseases or surgery were included in this survey. Moreover, pregnant girls and pediatrics taking medications were excluded. 3843 students were randomly selected for biochemical test and fasting blood sample was obtained from them. Protocol of this study have been explained in detail previously [9].
The study was approved by the Research and Ethics Council of Isfahan University of Medical Sciences (code: 194049). After explaining the objectives and protocols of the study, written informed consent and verbal consent were obtained from all the parents and students, respectively.

Anthropometric and laboratory measurements

Anthropometric measurements were performed by trained experts using calibrated instruments. Weight was measured to the nearest 0.1 kg while the subjects were minimally clothed. Height was measured in a standing position to the nearest 0.5 cm. Measurements were done without shoes [10]. Body mass index (BMI) was calculated as weight (kg) divided by square of height (m2). Waist circumference (WC) was measured us-ing non-elastic tape between the uppermost lateral border of right ilium and that of left ilium to the nearest 0.1 cm. Two measurements of blood pressure (BP) were done in the sitting position after 15 min of rest on the right arm using a standardized mercury sphygmomanometer. The first and fifth Korotkoff sounds were recorded as systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively. The mean of the two recorded values was considered as the subject’s BP. Mean arterial pressure (MAP) was calculated by this formula: [(SBP − DBP)/3] + DBP.
Fasting blood samples were drawn from participants after 12 to 14 h of overnight fast. Fasting blood glucose (FBG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides (TG) were measured enzymatically by Hitachi auto-analyzer (Tokyo, Japan).

Definition

Metabolic syndrome

In this study, MetS was defined according to the modified Adult Treatment Panel III (ATP III) criteria for the pediatric age group. MetS was defined as having at least three of the following: TG concentration of 150 mg/dL or greater; HDL-C concentration of 40 mg/dL or less; FBG concentration of 100 mg/dL or greater; abdominal obesity: waist to height ratio > 0.5; and either SBP or DBP greater than the 90th percentile for age, sex, and height [11].
Over weight and obesity in children were considered as a BMI between 85th percentile and 95th percentile and BMI greater than 95th percentile for age and sex according to WHO criteria, respectively. High LDL was defined as LDL > 110 mg/dL and High TC was defined as TC > 200 mg/dL.

Continuous mets (cMetS) score

The methodology of the cMetS score calculation was previously published in details [12]. In brief, the cMetS score was computed by standardizing the residuals (z-scores) of WC, MAP, HDL-C, TG, and FBG by regressing them according to age and sex. Because HDL-C is inversely related to MetS risk, it was multiplied by − 1. The cMetS score was calculated by aggregating the z scores for the individual variables. A higher cMetS score indicates a less favorable metabolic profile.

Statistical analysis

Analyses were conducted using STATA version 11.0 (STATA Statistical Software: Release 11. STATA Corp LP. Package, College Station, TX, USA). All variables were checked for normality and presented as the mean ± standard deviation or number (percentage). The independent sample t test was used to compare continuous variables and the Chi square test was used to compare proportions according to age and sex groups. The ANOVA was used to compare continuous variables between more than two groups. To estimate valid cut-off values of cMetS score for predicting metabolic syndrome, the receiver operation characteristic (ROC) curve analysis was performed with an estimation of the sensitivity and specificity. Data were also analyzed separately for sex and age categories. The estimated cut-off values were determined using the minimum value of which represents the maximum sum of sensitivity and specificity. The area under curve (AUC) shows the ability of cMetS score cut-off points to discriminate students with and without metabolic syndrome. P values less than 0.05 were considered as statistically significant.

Results

3843 students (52.3% boys) were participated in this study. The general characteristics of participants including anthropometric and biochemical measurements according to gender and age categories are presented in Table 1. Boys had an average higher weight, height and waist than girls in 7–10 and 15–18 years age groups (P < 0.001). However, girls had an average higher weight, height and BMI than boys in 11–14 years age group (P < 0.01). There were significant differences in mean SBP, DBP, MAP, FBS, TC and LDL-C between girls and boys in total participants (P < 0.05).
Table 1
Mean of cardiometabolic risk factors according to gender and age groups: the CASPIAN-V study
 
Total
Boys
Girls
P value
7–10 years
 Weight
27.69 (8.80)
28.36 (9.56)
27.06 (7.95)
< 0.001
 Height
130.05 (10.15)
130.87 (10.50)
129.27 (9.75)
< 0.001
 Waist
59.55 (9.05)
60.03 (9.54)
59.09 (8.53)
< 0.001
 SBP
93.99 (12.72)
93.85 (12.69)
94.12 (12.74)
0.46
 DBP
60.82 (10.35)
60.63 (10.31)
61 (10.39)
0.22
 FBS
91.67 (14.00)
92.31 (17.26)
91.05 (9.83)
0.12
 TG
87.12 (45.64)
86.78 (49.06)
87.45 (42.09)
0.80
 TC
154.72 (29.21)
155.43 (29.37)
154.03 (29.06)
0.41
 HDL-C
47.08 (10.60)
47.59 (10.80)
46.59 (10.38)
0.11
 MAP
71.88 (10.28)
71.70 (10.19)
72.04 (10.36)
0.26
 BMI
16.18 (4.03)
16.36 (4.65)
16 (3.32)
0.002
 WHtR
0.45 (.06)
0.45 (.06)
0.45 (.05)
0.36
 LDL-C
90.21 (24.12)
90.48 (23.46)
89.95 (24.75)
0.7
11–14 years
 Weight
42.05 (13.11)
41.43 (13.60)
42.68 (12.56)
< 0.001
 Height
148.85 (11.79)
148.43 (12.25)
149.28 (11.28)
0.007
 Waist
67.47 (11.18)
67.68 (11.25)
67.25 (11.11)
0.15
 SBP
99.43 (12.33)
99.16 (12.61)
99.71 (12.03)
0.1
 DBP
63.94 (9.97)
63.93 (10.20)
63.95 (9.74)
0.92
 FBS
91.77 (11.33)
92.18 (10.45)
91.33 (12.16)
0.12
 TG
87.76 (44.37)
85.67 (41.60)
89.96 (47.01)
0.04
 TC
154.07 (26.30)
153.29 (27.21)
154.89 (25.30)
0.21
 HDL-C
46.04 (9.75)
46.59 (10.06)
45.46 (9.38)
0.01
 MAP
75.77 (9.81)
75.68 (10.01)
75.87 (9.60)
0.45
 BMI
18.66 (4.41)
18.48 (4.76)
18.85 (4.01)
0.002
 WHtR
0.45 (.06)
0.45 (.06)
0.45 (.06)
0.002
 LDL-C
90.47 (21.69)
89.56 (22.72)
91.43 (20.53)
0.07
15–18 years
 Weight
57.68 (15.43)
59.75 (16.83)
55.31 (13.27)
< 0.001
 Height
164.01 (12.27)
167.71 (13.54)
159.80 (8.93)
< 0.001
 Waist
74.66 (11.70)
76.38 (12.76)
72.68 (10)
< 0.001
 SBP
105.25 (11.89)
106.55 (12.09)
103.76 (11.47)
< 0.001
 DBP
67.44 (10.01)
68.21 (10.38)
66.57 (9.48)
< 0.001
 FBS
91.44 (11.02)
91.66 (11.17)
91.14 (10.82)
0.45
 TG
89.50 (45.94)
89.59 (47.29)
89.38 (44.07)
0.93
 TC
152.53 (27.10)
150.18 (27.78)
155.75 (25.82)
0.001
 HDL-C
45.43 (9.54)
44.39 (9.45)
46.86 (9.49)
< 0.001
 MAP
80.05 (9.66)
80.98 (10.05)
78.98 (9.08)
< 0.001
 BMI
21.21 (4.42)
20.94 (4.44)
21.51 (4.37)
< 0.001
 WHtR
0.45 (0.06)
0.45 (0.06)
0.45 (0.06)
0.77
 LDL-C
89.20 (22.31)
87.87 (22.56)
91.02 (21.84)
0.02
Total
 Weight
41.39 (17.11)
42.36 (18.23)
40.41 (15.82)
< 0.001
 Height
146.56 (17.50)
148.15 (18.77)
144.93 (15.93)
< 0.001
 Waist
66.72 (12.17)
67.65 (12.87)
65.76 (11.33)
< 0.001
 SBP
99.17 (13.09)
99.55 (13.43)
98.77 (12.72)
< 0.001
 DBP
63.83 (10.43)
64.08 (10.70)
63.57 (10.14)
0.004
 FBS
91.65 (12.11)
92.06 (12.91)
91.20 (11.14)
0.026
 TG
88.04 (45.18)
87.15 (45.52)
89.02 (44.78)
0.200
 TC
153.85 (27.42)
152.96 (28.06)
154.83 (26.67)
0.035
 HDL-C
46.19 (9.97)
46.21 (10.17)
46.16 (9.75)
0.862
 MAP
75.61 (10.42)
75.91 (10.71)
75.31 (10.12)
0.001
 BMI
18.51 (4.71)
18.48 (4.96)
18.53 (4.43)
0.565
 WHtR
0.45 (0.06)
0.45 (0.06)
0.45 (0.06)
0.008
 LDL-C
90.05 (22.60)
89.31 (22.90)
90.86 (22.26)
0.034
Data are expressed as mean (SD)
BMI body mass index; DBP diastolic blood pressure; FBS fasting blood sugar; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; MAP mean arterial pressure; SBP systolic blood pressure; TC total cholesterol; TG triglycerides; WHtR waist to height ratio
Totally, 9.4% of pediatrics were overweight and 11.4% were obese. Prevalence of overweight was higher in girls than boys (10.2% vs. 8.7%) and prevalence of obesity was higher in boys than girls (12.5% vs. 10.3%) (P < 0.01). Table 2 presents the prevalence of cardiometabolic risk factors in children and adolescents according to age and gender categories. The prevalence of MetS in total participants was 5% with no significant difference between boys and girls. The mean of cMetS according to the number of MetS components was shown in Table 3. Pediatrics with higher number of MetS components had higher cMetS in all gender and age categories (P < 0.001).
Table 2
Prevalence of cardiometabolic risk factors in Iranian children and adolescents: the CASPIAN-V study
 
Total
Boys
Girls
P value
7–10 years
 Abdominal obesity
974 (20.4)
484 (20.7)
490 (20.0)
0.581
 Overweight
393 (8.2)
182 (7.8)
211 (8.6)
0.289
 Obese
530 (11.1)
298 (12.7)
232 (9.5)
< 0.001
 High FBG
47 (4.1)
31 (5.5)
16 (2.7)
0.019
 High TG
299 (26.1)
139 (24.6)
160 (27.5)
0.265
 High LDL-C
208 (18.1)
97 (17.2)
111 (19.1)
0.403
 High TC
72 (6.3)
37 (6.5)
35 (6.0)
0.709
 Low HDL-C
275 (24.0)
123 (21.8)
152 (26.1)
0.085
 Elevated systolic BP
229 (4.8)
89 (3.9)
140 (5.7)
0.003
 Elevated diastolic BP
427 (9.0)
206 (9.0)
221 (9.1)
0.949
 Elevated BP
515 (10.9)
239 (10.5)
276 (11.3)
0.340
 Mets
55 (4.9)
27 (4.9)
28 (5.0)
0.966
Number of mets
 0
487 (43.6)
238 (43.2)
249 (44.1)
0.802
 1
391 (35.0)
201 (36.5)
190 (33.6)
 2
183 (16.4)
85 (15.4)
98 (17.3)
 > 3
55 (5.0)
27 (4.9)
28 (5.0)
11–14
 Abdominal obesity
1156 (20.9)
606 (21.7)
550 (20.1)
0.151
 Overweight
567 (10.2)
260 (9.3)
307 (11.2)
0.019
 Obese
675 (12.2)
372 (13.3)
303 (11.0)
0.011
 High FBG
71 (4.3)
37 (4.4)
34 (4.2)
0.864
 High TG
457 (27.6)
219 (25.9)
238 (29.4)
0.108
 High LDL-C
282 (17.0)
147 (17.4)
135 (16.7)
0.710
 High TC
74 (4.5)
40 (4.7)
34 (4.2)
0.605
 Low HDL-C
428 (25.9)
206 (24.3)
222 (27.4)
0.151
 Elevated systolic BP
158 (2.9)
86 (3.1)
72 (2.6)
0.323
 Elevated diastolic BP
729 (13.2)
365 (13.1)
364 (13.4)
0.770
 Elevated BP
775 (14.1)
388 (13.9)
387 (14.2)
0.760
 Mets
85 (5.3)
46 (5.6)
39 (5.0)
0.598
Number of mets
 0
628 (39.0)
334 (40.4)
294 (37.5)
0.487
 1
580 (36.0)
296 (35.8)
284 (36.3)
 2
316 (19.6)
150 (18.2)
166 (21.2)
 > 3
85 (5.3)
46 (5.6)
39 (5)
15–18
 Abdominal obesity
842 (22.2)
460 (22.7)
382 (21.6)
0.421
 Overweight
370 (9.7)
179 (8.8)
191 (10.7)
0.046
 Obese
410 (10.8)
226 (11.1)
184 (10.3)
0.433
 High FBG
43 (4.1)
28 (4.7)
15 (3.4)
0.319
 High TG
309 (29.7)
183 (30.4)
126 (28.6)
0.538
 High LDL-C
184 (17.7)
97 (16.1)
87 (19.8)
0.126
 High TC
43 (4.1)
23 (3.8)
20 (4.5)
0.561
 Low HDL-C
431 (41.4)
329 (54.7)
102 (23.2)
< 0.001
 Elevated systolic BP
51 (1.4)
35 (1.7)
16 (0.9)
0.029
 Elevated diastolic BP
294 (7.8)
175 (8.7)
119 (6.8)
0.031
 Elevated BP
314 (8.3)
188 (9.3)
126 (7.2)
0.018
 Mets
48 (4.8)
35 (6.0)
13 (3.1)
0.035
Number of mets
 0
328 (32.6)
134 (22.8)
194 (46.2)
< 0.001
 1
386 (38.3)
250 (42.6)
136 (32.4)
 2
245 (24.3)
168 (28.6)
77 (18.3)
 > 3
48 (4.8)
35 (6)
13 (3.1)
Total
 Abdominal obesity
2972 (21.1)
1550 (21.6)
1422 (20.5)
0.087
 Overweight
1330 (9.4)
621 (8.7)
709 (10.2)
0.002
 Obese
1615 (11.4)
896 (12.5)
719 (10.3)
< 0.001
 High FBG
161 (4.2)
96 (4.8)
65 (3.8)
0.060
 High TG
1065 (27.7)
541 (26.9)
524 (28.6)
0.228
 High LDL-C
674 (17.5)
341 (16.9)
333 (18.2)
0.310
 High TC
189 (4.9)
100 (5.0)
89 (4.9)
0.878
 Low HDL-C
1134 (29.5)
658 (32.7)
476 (26.0)
< 0.001
Elevated systolic BP
438 (3.1)
210 (3.0)
228 (3.3)
0.255
 Elevated diastolic BP
1450 (10.4)
746 (10.5)
704 (10.2)
0.510
 Elevated BP
1604 (11.5)
815 (11.5)
789 (11.4)
0.877
 Mets
188 (5)
108 (5.5)
80 (4.5)
0.174
Number of mets components
 0
1443 (38.7)
706 (35.9)
737 (41.7)
0.005
 1
1357 (36.4)
747 (38.0)
610 (34.5)
 2
744 (19.9)
403 (20.5)
341 (19.3)
 > 3
161 (5.1)
108 (5.5)
80 (4.5)
Data are expressed as number (%)
Overweight: BMI; 85th–95th; obesity, BMI > 95th; low HDL: < 40 mg/dL (except in boys 15–19 y old, that cut-off was < 45 mg/dL); high LDL: > 110 mg/dL; high TG: 100 mg/dL; high TC: > 200 mg/dL; elevated FBS > 100 mg/dL; high blood pressure: > 90th (adjusted by age, sex, height)
BP blood pressure; TG triglycerides; FBG fasting blood glucose; HDL-C high-density lipoprotein-cholesterol; TC total cholesterol; LDL-C low-density lipoprotein cholesterol
Table 3
Mean of Continuous Metabolic Syndrome score by Mets and numbers of MetS components
  
Total
Boys
Girls
cMetS score
cMetS score
cMetS score
MetS
 
7–10
11–14
15–18
7–10
11–14
15–18
7–10
11–14
15–18
Yes
4.4 ± 2.02
4.2 ± 1.62
4.2 ± 2.35
4.2 ± 2.41
4.2 ± 1.69
4.3 ± 2.45
4.6 ± 1.58
4.3 ± 1.56
3.8 ± 2.15
No
− 0.4 ± 2.36
− 0.2 ± 2.3
− 0.3 ± 2.45
− 0.4 ± 2.58
− 0.4 ± 2.24
− 0.2 ± 2.52
− 0.3 ± 2.12
0.004 ± 2.34
− 0.5 ± 2.35
P value
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
MetS components
0
− 1.7 ± 1.74
− 1.7 ± 1.78
− 2.2 ± 1.83
− 1.9 ± 1.84
− 1.8 ± 1.8
− 2.6 ± 1.8
− 1.6 ± 1.62
− 1.5 ± 1.75
− 1.9 ± 1.81
1
0.1 ± 1.72
0.1 ± 1.82
− 0.2 ± 1.78
0.08 ± 1.79
− 0.09 ± 1.69
− 0.3 ± 1.82
0.1 ± 1.65
0.3 ± 1.92
− 0.1 ± 1.71
2
2.1 ± 2.44
2.2 ± 1.63
1.8 ± 2.13
2.4 ± 3.06
2.09 ± 1.57
1.7 ± 2.21
1.9 ± 1.7
2.3 ± 1.68
2.04 ± 1.95
+3
4.4 ± 2.02
4.2 ± 1.62
4.2 ± 2.35
4.2 ± 2.41
4.2 ± 1.69
4.3 ± 2.45
4.6 ± 1.58
4.3 ± 1.56
3.8 ± 2.15
Total
− 0.1 ± 2.57
0.03 ± 2.48
− 0.1 ± 2.64
− 0.2 ± 2.76
− 0.1 ± 2.45
0.03 ± 2.74
− 0.1 ± 2.37
0.2 ± 2.5
− 0.4 ± 2.46
P value
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
Data are expressed as mean ± SD
Metabolic syndrome: ATP-III criteria; Abdominal obesity: WC > 90th percentile; Low HDL: HDL < 40 mg/dL (except in boys 15–19 years old, that cut-off was < 45 mg/dL); High TG: TG > 100 mg/dL; High FBG: FBG > 100 mg/dL; High blood pressure: BP > 90th (adjusted by age, sex, height)
Table 4 shows the cut-off points of cMetS to predict MetS with sensitivity, specificity and AUC for gender and age categories. In boys, cMetS values for predicting MetS in 7–10, 11–14 and 15–18 years age groups were 1.95, 1.70 and 2.44, respectively. These scores for girls were 2.80, 2.72 and 2.34 in different age categories, respectively. The overall cMetS cut-off point was 1.76 (sensitivity 93%, specificity 82% and AUC 94%) in total pediatrics, 1.79 (sensitivity 92%, specificity 82% and AUC 93%) in boys and 2.72 (sensitivity 90%, specificity 91% and AUC 95%) in girls. In all groups, cMetS performed highly accurate in predicting students with MetS (90 < AUC < 100%). The ROC curves of the cMetS for MetS stratified by gender are displayed in Fig. 1.
Table 4
Receiver operator curve for cMetS score for identifying children with MetS
 
cMetS score cut-off points (95% CI)
Sensitivity (95% CI)
Specificity (95% CI)
AUC (95% CI)
7–10 years
 Boy
1.95 (1.23–2.68)
96 (92–100)
86 (80–92)
93 (91–96)
 Girl
2.80 (2.04–3.56)
93 (86–99)
93 (87–99)
97 (95–99)
 Total
1.97 (1.51–2.43)
96 (91–100)
86 (83–90)
95 (94–97)
11–14 years
 Boy
1.70 (1.09–2.30)
98 (90–100)
82 (75–89)
95 (93–97)
 Girl
2.72 (2.07–3.36)
92 (85–99)
90 (82–98)
95 (93–97)
 Total
1.75 (0.78–2.72)
96 (88–100)
81 (70–92)
95 (93–97)
15–18 years
 Boy
2.44 (0.92–3.97)
80 (66–94)
86 (71–99)
90 (86–94)
 Girl
2.34 (0.90–3.96)
82 (67–95)
87 (71–99)
93 (88–98)
 Total
2.38 (0.68–4.07)
81 (68–94)
87 (71–99)
92 (88–95)
 Boy (7–18 years)
1.79 (1.16–2.41)
92 (86–97)
82 (76–89)
93 (91–95)
 Girl (7–18 years)
2.72 (2.31–3.12)
90 (83–97)
91 (88–95)
95 (94–97)
 Total (7–18 years)
1.76 (1.16–2.36)
93 (86–100)
82 (75–88)
94 (93–95)
Metabolic syndrome: ATP-III criteria; Abdominal obesity: WC > 90th percentile; Low HDL: HDL < 40 mg/dL (except in boys 15–19 years old, that cut-off was < 45 mg/dL); High TG: TG > 100 mg/dL; High FBG: FBG > 100 mg/dL; High blood pressure: BP > 90th (adjusted by age, sex, height)
CI confidence interval; AUC area under curve, shown as percentage

Discussion

In the present study, we determined the age- and gender- specific optimal cutoff points of cMetS in correlation to MetS and its validity in a large population-based sample of children and adolescents.
Our results obviously demonstrated an association between cMetS and MetS components. In addition, by ROC analyses, we indicated the optimal cutoff points for cMetS in various age groups according to gender. Results of the ROC analysis demonstrated a cMetS of 1.76 as the optimal cutoff point in 7–18 years old subjects in both gender. The area under the curve (AUC) for this index was 94%, which shows cMetS score is highly accurate and sensitive enough in predicting the presence of MetS in children and adolescents. The optimal cMetS cut-off points for boys and girls were 1.79 and 2.72, respectively in the total study. Our study showed that the cMetS was higher in subjects with MetS and it enhanced with increasing number of MetS factors. Those with equal or more than three risk factors had the highest cMetS. Our findings are consistent with some previous findings and support the use of cMetS in epidemiological surveys in children and adolescents [1316].
Kelly et al. [17] have demonstrated significant relationship between childhood MetS, defined by cMetS, and adult cardiovascular risk. Okosun et al. [18] have shown an association between the cMetS and having 1 to 5 components of MetS.
Because of the lack of adequate and accepted criteria for the definition of MetS in pediatric age group, and increasing prevalence rate of MetS in children and adolescents, metabolic risk scores have been used to indicate clustering of metabolic risk factors. cMetS is calculated from continuous variables for the MetS components. cMetS in childhood has been correlated with the progress of MetS in young adulthood, which confirms the public health relevance of the investigation on cMetS. For calculating cMetS, it is assumed that all components of MetS are equally important and responsible in determining the cardiovascular risk factors [14, 19, 20].
The results of our previous study confirmed the validity of the cMetS score in a population-based sample of Iranian children and adolescents. Our findings serve as confirmatory evidence that cMetS can be used as an appropriate index for investigating the association between potential risk factors and MetS in epidemiological studies in the pediatric population.
Compared with individual MetS components, cMetS can investigate the risk of metabolic abnormalities by a more practical approach. cMetS is more sensitive and less error- prone and might increase the statistical power compared with binary definition of MetS particularly at early stages of metabolic abnormalities [21, 22]. Therefore, the use of cMetS has been supported as an alternative to the categorical measures that are often used for MetS in epidemiological studies [5, 23]. However, the binary or categorical definition of MetS remains advantageous for clinical practice [24].
The cMetS score is sample-specific and this is one of the main limitations of this score. Thus, the mean cMetS obtained from this study cannot be generalized and compared to other studies unless the data distribution, the demographic characteristics, and the measures of central tendency and variability of data would be similar. cMetS cutoff points must be calculated and validated for each study population. In addition, comparison of results in various studies is difficult because of using of different variables and statistical approaches [25].
Eisenmann recommended five key metabolic syndrome variables in the calculation of the cMetS in the pediatric research. These variables include central obesity (waist circumference, body mass index or skin fold thickness), low HDL-C, elevated TG, elevated BP (systolic, diastolic or mean arterial pressure) and abnormal glucose metabolism (impaired fasting glucose, impaired glucose tolerance or HOMA). If the validity of cMetS would be confirmed as an index for modeling pediatric MetS, it can be used as simple and practical tool in future pediatric epidemiological research, clinical medicine, and public health surveys for prevention, diagnosis and management of MetS and its components in the pediatric age group [25].

Conclusions

Our findings confirmed the association of cMetS with existence of MetS in the pediatric age group. In addition, its validity was confirmed. This score is becoming widely used in pediatric epidemiological research. Further studies are needed in different populations for using this score in clinical practice.

Authors’ contributions

MH, H-SE, MQ: Concept; RH, MQ, RK: Design; Data RH, MEM, HZ, MT, TA, AM-G, GS, SB: Collection or Processing; H-SE, MQ: Analysis or Interpretation; MH, H-SE, MQ: Literature Search; MH, H-SE, RK: Writing. All authors read and approved the final manuscript.

Acknowledgements

The authors are thankful of all participants and large team working on this project in different provinces.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Not applicable.
The study was approved by the Research and Ethics Council of Isfahan University of Medical Sciences (Code 194049). After explaining the objectives and protocols of the study, written informed consent and verbal consent were obtained from all the parents and students, respectively.

Funding

Isfahan University of Medical Sciences and other relevant national regulatory organizations (Project Number 194049).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.CrossRefPubMed Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.CrossRefPubMed
2.
Zurück zum Zitat Ahrens W, Moreno LA, Marild S, Molnar D, Siani A, De Henauw S, et al. Metabolic syndrome in young children: definitions and results of the IDEFICS study. Int J Obes. 2014;38(Suppl 2):S4–14.CrossRef Ahrens W, Moreno LA, Marild S, Molnar D, Siani A, De Henauw S, et al. Metabolic syndrome in young children: definitions and results of the IDEFICS study. Int J Obes. 2014;38(Suppl 2):S4–14.CrossRef
4.
Zurück zum Zitat Koskinen J, Magnussen CG, Sinaiko A, Woo J, Urbina E, Jacobs DR Jr, et al. Childhood age and associations between childhood metabolic syndrome and adult risk for metabolic syndrome, type 2 diabetes mellitus and carotid intima media thickness: the International Childhood Cardiovascular Cohort Consortium. J Am Heart Assoc. 2017;6(8):e005632.CrossRefPubMedPubMedCentral Koskinen J, Magnussen CG, Sinaiko A, Woo J, Urbina E, Jacobs DR Jr, et al. Childhood age and associations between childhood metabolic syndrome and adult risk for metabolic syndrome, type 2 diabetes mellitus and carotid intima media thickness: the International Childhood Cardiovascular Cohort Consortium. J Am Heart Assoc. 2017;6(8):e005632.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pandit D, Chiplonkar S, Khadilkar A, Kinare A, Khadilkar V. Efficacy of a continuous metabolic syndrome score in Indian children for detecting subclinical atherosclerotic risk. Int J Obes. 2011;35(10):1318–24.CrossRef Pandit D, Chiplonkar S, Khadilkar A, Kinare A, Khadilkar V. Efficacy of a continuous metabolic syndrome score in Indian children for detecting subclinical atherosclerotic risk. Int J Obes. 2011;35(10):1318–24.CrossRef
6.
Zurück zum Zitat Olza J, Aguilera CM, Gil-Campos M, Leis R, Bueno G, Valle M, et al. A continuous metabolic syndrome score is associated with specific biomarkers of inflammation and CVD risk in prepubertal children. Ann Nutr Metab. 2015;66(2–3):72–9.CrossRefPubMed Olza J, Aguilera CM, Gil-Campos M, Leis R, Bueno G, Valle M, et al. A continuous metabolic syndrome score is associated with specific biomarkers of inflammation and CVD risk in prepubertal children. Ann Nutr Metab. 2015;66(2–3):72–9.CrossRefPubMed
7.
Zurück zum Zitat Hesse MB, Young G, Murray RD. Evaluating health risk using a continuous metabolic syndrome score in obese children. J Pediatr Endocrinol Metab. 2016;29(4):451–8.CrossRefPubMed Hesse MB, Young G, Murray RD. Evaluating health risk using a continuous metabolic syndrome score in obese children. J Pediatr Endocrinol Metab. 2016;29(4):451–8.CrossRefPubMed
8.
Zurück zum Zitat Prochotska K, Kovacs L, Vitariusova E, Feber J. Is arterial stiffness predicted by continuous metabolic syndrome score in obese children? J Am Soc Hypertens. 2016;10(1):47–54.CrossRefPubMed Prochotska K, Kovacs L, Vitariusova E, Feber J. Is arterial stiffness predicted by continuous metabolic syndrome score in obese children? J Am Soc Hypertens. 2016;10(1):47–54.CrossRefPubMed
9.
Zurück zum Zitat Motlagh ME, Ziaodini H, Qorbani M, Taheri M, Aminaei T, Goodarzi A, et al. Methodology and early findings of the fifth survey of childhood and adolescence surveillance and prevention of adult noncommunicable disease: the CASPIAN-V Study. Int J Prev Med. 2017;8:4.CrossRefPubMedPubMedCentral Motlagh ME, Ziaodini H, Qorbani M, Taheri M, Aminaei T, Goodarzi A, et al. Methodology and early findings of the fifth survey of childhood and adolescence surveillance and prevention of adult noncommunicable disease: the CASPIAN-V Study. Int J Prev Med. 2017;8:4.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Organization WH. Physical status: the use of and interpretation of anthropometry. Geneva: Report of a WHO Expert Committee. 1995. Organization WH. Physical status: the use of and interpretation of anthropometry. Geneva: Report of a WHO Expert Committee. 1995.
11.
Zurück zum Zitat Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents. Lancet. 2007;369(9579):2059–61.CrossRefPubMed Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents. Lancet. 2007;369(9579):2059–61.CrossRefPubMed
12.
Zurück zum Zitat Shafiee G, Kelishadi R, Heshmat R, Qorbani M, Motlagh ME, Aminaee T, et al. First report on the validity of a continuous metabolic syndrome score as an indicator for metabolic syndrome in a national sample of paediatric population—the CASPIAN-III study. Endokrynol P. 2013;64(4):278–84.CrossRef Shafiee G, Kelishadi R, Heshmat R, Qorbani M, Motlagh ME, Aminaee T, et al. First report on the validity of a continuous metabolic syndrome score as an indicator for metabolic syndrome in a national sample of paediatric population—the CASPIAN-III study. Endokrynol P. 2013;64(4):278–84.CrossRef
13.
Zurück zum Zitat Wijndaele K, Beunen G, Duvigneaud N, Matton L, Duquet W, Thomis M, et al. A continuous metabolic syndrome risk score: utility for epidemiological analyses. Diabetes Care. 2006;29(10):2329.CrossRefPubMed Wijndaele K, Beunen G, Duvigneaud N, Matton L, Duquet W, Thomis M, et al. A continuous metabolic syndrome risk score: utility for epidemiological analyses. Diabetes Care. 2006;29(10):2329.CrossRefPubMed
14.
Zurück zum Zitat Hillier TA, Rousseau A, Lange C, Lepinay P, Cailleau M, Novak M, et al. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia. 2006;49(7):1528–35.CrossRefPubMedPubMedCentral Hillier TA, Rousseau A, Lange C, Lepinay P, Cailleau M, Novak M, et al. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia. 2006;49(7):1528–35.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Okosun IS, Boltri JM, Lyn R, Davis-Smith M. Continuous metabolic syndrome risk score, body mass index percentile, and leisure time physical activity in American children. J Clin Hypertens. 2010;12(8):636–44.CrossRef Okosun IS, Boltri JM, Lyn R, Davis-Smith M. Continuous metabolic syndrome risk score, body mass index percentile, and leisure time physical activity in American children. J Clin Hypertens. 2010;12(8):636–44.CrossRef
16.
Zurück zum Zitat Eisenmann JC, Laurson KR, DuBose KD, Smith BK, Donnelly JE. Construct validity of a continuous metabolic syndrome score in children. Diabetol Metab Syndr. 2010;2:8.CrossRefPubMedPubMedCentral Eisenmann JC, Laurson KR, DuBose KD, Smith BK, Donnelly JE. Construct validity of a continuous metabolic syndrome score in children. Diabetol Metab Syndr. 2010;2:8.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Kelly AS, Steinberger J, Jacobs DR, Hong CP, Moran A, Sinaiko AR. Predicting cardiovascular risk in young adulthood from the metabolic syndrome, its component risk factors, and a cluster score in childhood. Pediatr Obes. 2011;6(2–2):e283–9.CrossRef Kelly AS, Steinberger J, Jacobs DR, Hong CP, Moran A, Sinaiko AR. Predicting cardiovascular risk in young adulthood from the metabolic syndrome, its component risk factors, and a cluster score in childhood. Pediatr Obes. 2011;6(2–2):e283–9.CrossRef
18.
Zurück zum Zitat Okosun IS, Lyn R, Davis-Smith M, Eriksen M, Seale P. Validity of a continuous metabolic risk score as an index for modeling metabolic syndrome in adolescents. Ann Epidemiol. 2010;20(11):843–51.CrossRefPubMed Okosun IS, Lyn R, Davis-Smith M, Eriksen M, Seale P. Validity of a continuous metabolic risk score as an index for modeling metabolic syndrome in adolescents. Ann Epidemiol. 2010;20(11):843–51.CrossRefPubMed
19.
Zurück zum Zitat DuBose KD, Eisenmann JC, Donnelly JE. Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children. Pediatrics. 2007;120(5):e1262–8.CrossRefPubMed DuBose KD, Eisenmann JC, Donnelly JE. Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children. Pediatrics. 2007;120(5):e1262–8.CrossRefPubMed
20.
Zurück zum Zitat Gurka MJ, Ice CL, Sun SS, Deboer MD. A confirmatory factor analysis of the metabolic syndrome in adolescents: an examination of sex and racial/ethnic differences. Cardiovasc Diabetol. 2012;11:128.CrossRefPubMedPubMedCentral Gurka MJ, Ice CL, Sun SS, Deboer MD. A confirmatory factor analysis of the metabolic syndrome in adolescents: an examination of sex and racial/ethnic differences. Cardiovasc Diabetol. 2012;11:128.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Brage S, Wedderkopp N, Ekelund U, Franks PW, Wareham NJ, Andersen LB, et al. Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children: the European Youth Heart Study (EYHS). Diabetes Care. 2004;27(9):2141–8.CrossRefPubMed Brage S, Wedderkopp N, Ekelund U, Franks PW, Wareham NJ, Andersen LB, et al. Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children: the European Youth Heart Study (EYHS). Diabetes Care. 2004;27(9):2141–8.CrossRefPubMed
22.
Zurück zum Zitat Viitasalo A, Lakka TA, Laaksonen DE, Savonen K, Lakka HM, Hassinen M, et al. Validation of metabolic syndrome score by confirmatory factor analysis in children and adults and prediction of cardiometabolic outcomes in adults. Diabetologia. 2014;57(5):940–9.CrossRefPubMed Viitasalo A, Lakka TA, Laaksonen DE, Savonen K, Lakka HM, Hassinen M, et al. Validation of metabolic syndrome score by confirmatory factor analysis in children and adults and prediction of cardiometabolic outcomes in adults. Diabetologia. 2014;57(5):940–9.CrossRefPubMed
23.
Zurück zum Zitat Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology. 1992;3(5):434–40.CrossRefPubMed Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology. 1992;3(5):434–40.CrossRefPubMed
24.
Zurück zum Zitat Gurka MJ, Golden SH, Musani SK, Sims M, Vishnu A, Guo Y, et al. Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk in Communities Study and Jackson Heart Study. Diabetologia. 2017;60(7):1261–70.CrossRefPubMed Gurka MJ, Golden SH, Musani SK, Sims M, Vishnu A, Guo Y, et al. Independent associations between a metabolic syndrome severity score and future diabetes by sex and race: the Atherosclerosis Risk in Communities Study and Jackson Heart Study. Diabetologia. 2017;60(7):1261–70.CrossRefPubMed
Metadaten
Titel
Validity of a continuous metabolic syndrome score as an index for modeling metabolic syndrome in children and adolescents: the CASPIAN-V study
verfasst von
Ramin Heshmat
Motahar Heidari
Hanieh-Sadat Ejtahed
Mohammad Esmaeil Motlagh
Armita Mahdavi-Gorab
Hasan Ziaodini
Majzoubeh Taheri
Gita Shafiee
Shaghayegh Beshtar
Mostafa Qorbani
Roya Kelishadi
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
Diabetology & Metabolic Syndrome / Ausgabe 1/2017
Elektronische ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-017-0291-4

Weitere Artikel der Ausgabe 1/2017

Diabetology & Metabolic Syndrome 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.